By Business/Source
Currency:USD
2025/FY
Stock NameRevenueRatio
Development of novel therapies across a range of cancers593K100.00%
By Country/Region
Currency:USD
2025/FY
Stock NameRevenueRatio
United States (U.S.)593K100.00%